Dear Editor, The RUNX gene family includes three evolutionarily conserved genes (RUNX1, RUNX2, and RUNX3) encoding transcription factors involved in cell lineage differentiation during development and various forms of cancer [1] . RUNX1 gene (also known as AML1 PEBP2αB or CBFA2), located in chromosome 21q22.3, is crucial for the establishment of definite hematopoiesis and the generation of hematopoietic stem cells in the embryo. RUNX1 acts as a key regulator of hematopoiesis through the regulation of various hematopoietic genes [1] [2] [3] .
RUNX1 impairment resulting from mutation, deletion, translocation, or amplification is reported to contribute to the pathogenesis of acute leukemias [4] . We report here distinct clonal anomalies involving the RUNX1 gene occurring in the course of the disease in a patient with acute myeloblastic leukemia (AML).
This 51-year-old man was first seen in February 2006 because of persistent rhinitis and recurrent epistaxis. Physical examination showed no adenopathy or hepatosplenomegaly. The peripheral blood count revealed a leukocytosis of 8.6×10
9 /l with 37% blasts, 12% neutrophils, 25% monocytes and promonocytes, a hemoglobin level of 10.1 g/l and a platelet count of 105×10 9 /l. The bone marrow aspirate showed hypercellularity with 68% blasts positive for CD13, CD33, CD117, MPO, and CD65. AML-M1 was diagnosed (FAB classification). The patient received induction chemotherapy according to the LAM2001 protocol (idarubicin and cytarabin) followed by re-induction because of chemoresistance at day15. The patient also received central nervous system prophylaxis with intrathecal injections. A complete remission was obtained. granulocytic sarcoma localized at the penis, with normal bone marrow morphology, was diagnosed in July 2008. Surgery followed by radiotherapy was applied. In November 2008, a gingival granulocytic sarcoma and a medullar relapse, with 45% blasts, were observed. Induction chemotherapy failed to obtain a remission, the sole result being a stabilization of the leukocytosis.
R-banded karyotypes were established from sequential bone marrow aspirate samples that had been cultured for 24 h synchronized by FUdR. Fluorescence in situ hybridization (FISH) analyses were performed using whole chromosome painting (WCP) of chromosomes 3, 7, 11, 21, 22, and arm-specific probes (PCP) 3p, 3q (QBIOgene®, Illkirch, France), telomeric probes of chromosome 3 (Abbott®, Rungis, France) and locus specific identifier MLL, BCR/ABL1, TEL/AML1 (Abbott®) as well as bacterial artificial chromosome (BAC) clones RP11-13M6, RP11-198D7, RP11-434P20, RP11-91K9, RP11-245C23, RP11-12L14 located on the long arm of chromosome 3 (3q26.3) and BAC RP11-77G18 covering AML1.
At diagnosis, a sole abnormal clone was detected. Karyotype was interpreted as 46,XY,der(7)t(7;11)(q31; q14) [5] Fig. 1b) . No MLL amplification was detected by FISH. FISH with BAC clone (RP11-77G18) covering the RUNX1 gene showed one signal on der(21) and one signal on der(3; Fig. 2b ). Breakpoints on 3q occurred between RP11-434P20 and RP11-245C23 with deletion of RP11-91K9. This translocation disappeared; interphase FISH on cells from the (Table 1) . FISH analyses using TEL/AML1 probe were performed retrospectively at diagnosis and all along the disease. They revealed an abnormal clone with RUNX1 deletion (undetected by banding techniques), distinct from the clone with MLL amplification, present at diagnosis (Table 1; Fig. 2a) . With chemotherapy and BMT, this clone disappeared until July 2008 before being again observed in bone marrow cells 4 months before the second medullary relapse was evidenced ( Table 1) .
The RUNX1 gene is known to be frequently deregulated in human leukemia through different mechanisms [4] . In the case reported here, at the time of AML diagnosis, an overlooked clone with RUNX1 deletion was present. It coexisted with a partial monosomic 7q/ trisomic 11q clone, consistently observed in AML. Although hemizygous loss of RUNX1 function is suspected to play a key role in the development of myelodysplastic syndrome/acute myeloblastic leukemia (MDS/ AML) patients, it is not sufficient to develop overt leukemia and acquisition of additional genetic alterations is necessary [6, 7] . RUNX1 mutations were found to be significantly associated with monosomy 7 or partial deletion of the long arm of chromosome seven in studies of MDS/AML patients [5, 7] . RUNX1 mutations were suggested to be the major factor to develop MDS/AML in conjunction with additional gene alterations belonging to the RTK-RAS signal transduction pathway [7] . Interestingly, in our case, RUNX1 deletion and 7q deletion did not occur in the same cells. However, an additional RUNX1 mutation could not be excluded.
At first relapse, none of the clones present at diagnosis was detected but the RUNX1 gene was rearranged in a complex 3;21 translocation involving five chromosomes. The t(3;21)(q26;q22) is a recurrent abnormality in therapyrelated AML, occurring primarily after treatment with topoisomerase II inhibitors [8] . Three genes at 3q26, EVI1, MDS1 and EAP are known to be fused with RUNX1 in the (3;21) translocation [9, 10] . In our case, the breakpoint at 3q26 is 8 megabases distal to the EVI1-MDS1-EAP cluster, arguing for the involvement of another gene. Three genes have been mapped in the interval between RP11-434P20 and RP11-245C23. These are KCNMB2, a calcium channel, WIG1, a wildtype p53-induced gene, and TBL1XR1, a transducin-beta-like 1 C 3q 21q 3p 11q 22q Fig. 1 Conventional cytogenetics. a Partial R-banded karyotype at diagnosis showing der(7)t(7;11)(q31;q14). b R-banded karyotype at first relapse following the first BMT: 46,XY,t(3;11;22;21;3)(p13;q14;q12;q22;q26) receptor 1 (http://www.ncbi.nlm.nih.gov/mapview/). WIG1 could be a good candidate to be fused with RUNX1 as it is located in the nucleus and contains three zinc finger domains and a putative nuclear localization signal. Unfortunately, no cells taken at first relapse were available for further cytogenetic and molecular studies to characterize this partner gene.
This report raises the question of whether the RUNX1 gene was constitutively prone to breakage in the patient. Whether there was a pre-leukemic stem cell in which acquired RUNX1 alterations cooperated with pre-existing lesions to result in full blown acute leukemia remains hypothetical. 
